khellin has been researched along with Acne in 47 studies
Khellin: A vasodilator that also has bronchodilatory action. It has been employed in the treatment of angina pectoris, in the treatment of asthma, and in conjunction with ultraviolet light A, has been tried in the treatment of vitiligo. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1024)
khellin : A furanochrome in which the basic tricyclic skeleton is substituted at positions 4 and 9 with methoxy groups and at position 7 with a methyl group. A major constituent of the plant Ammi visnaga it is a herbal folk medicine used for various illnesses, its main effect being as a vasodilator.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to investigate the prevalences of hypertrophic scars and keloids in acne patients treated with oral isotretinoin." | 7.83 | Observational retrospective study evaluating the effects of oral isotretinoin in keloids and hypertrophic scars. ( Bagatin, E; Gonçalves, RG; Guadanhim, LR, 2016) |
| "Isotretinoin-induced keloid formation has occasionally been reported in patients who have undergone dermabrasion or laser treatment." | 7.73 | Possible isotretinoin-induced keloids in a patient with Behçet's disease. ( Dogan, G, 2006) |
| "We report the observation of delayed wound healing and keloid formation in three patients, following dermabrasion or Argon laser treatment administered while they were receiving isotretinoin for acne or rosacea." | 7.67 | Delayed wound healing and keloid formation following argon laser treatment or dermabrasion during isotretinoin treatment. ( Zachariae, H, 1988) |
| "A case report of massive mandibular keloid with severe infection induced by acne achieved resolution of skin lesions after combined treatment with surgery and high concentration single-dose 5-aminolevulinic acid photodynamic therapy (5-ALA PDT)." | 4.02 | A massive mandibular keloid with severe infection: What is your treatment? ( Chen, XD; Gao, LM; Wu, XY; Zhao, LT, 2021) |
| "The aim of this study was to investigate the prevalences of hypertrophic scars and keloids in acne patients treated with oral isotretinoin." | 3.83 | Observational retrospective study evaluating the effects of oral isotretinoin in keloids and hypertrophic scars. ( Bagatin, E; Gonçalves, RG; Guadanhim, LR, 2016) |
| "Isotretinoin-induced keloid formation has occasionally been reported in patients who have undergone dermabrasion or laser treatment." | 3.73 | Possible isotretinoin-induced keloids in a patient with Behçet's disease. ( Dogan, G, 2006) |
| "We report the observation of delayed wound healing and keloid formation in three patients, following dermabrasion or Argon laser treatment administered while they were receiving isotretinoin for acne or rosacea." | 3.67 | Delayed wound healing and keloid formation following argon laser treatment or dermabrasion during isotretinoin treatment. ( Zachariae, H, 1988) |
| "Cryoanesthesia is ideally intended to cool only the epidermis during treatment and has advantage which did not require application time." | 3.30 | Cold anesthesia for pain reduction during intralesional steroid injection for nodulocystic acne. ( Kim, GH; Koh, YG; Park, KY; Park, SJ; Rho, NK; Shin, SH, 2023) |
| " No serious adverse reactions and good tolerability were reported in the included studies." | 3.01 | Efficacy and safety of needle-free jet injector-assisted intralesional treatments in dermatology-a systematic review. ( Bekkers, VZ; Bik, L; Prens, EP; van Doorn, MBA; van Huijstee, JC; Wolkerstorfer, A, 2023) |
| "Hypertrophic scars and keloids may complicate wound healing secondary to trauma or surgery." | 2.69 | Treatment of inflamed hypertrophic scars using intralesional 5-FU. ( Fitzpatrick, RE, 1999) |
| "Acne scarring can be classified into atrophic icepick, boxcar, and rolling scars in addition to keloidal and hypertrophic scars." | 2.53 | Acne Scar Treatment: A Multimodality Approach Tailored to Scar Type. ( Fabi, SG; McGraw, T; Taylor, M; Zaleski-Larsen, LA, 2016) |
| "Acne scarring is common but difficult to treat." | 2.46 | [Therapy of acne scars]. ( Jansen, T; Podda, M, 2010) |
| "The use of several modalities for the treatment of acne scarring is advocated; these include dermabrasion, punch-transplant replacement techniques, and collagen implants." | 2.36 | Cosmetic dermatologic surgery. ( Stegman, SJ; Tromovitch, TA, 1982) |
| " Combined with knowledge of the relevant literature, the mechanisms, types, and timing and dose, and reflect on balancing of recurrence rates and complications to deepen our understanding of the disease." | 1.91 | Rare Complication of Massive Depigmentation After Postoperative Treatment of Giant Keloid Combined With Strontium-90. ( Li, J; Liu, J; Wang, X; Wang, Y; Zhang, W; Zhang, Z, 2023) |
| "Acne vulgaris is a troubling skin disease known to have both physiologic and psychological effects on patients." | 1.72 | Acne Scars: An Update on Management ( Alajmi, A; Alazemi, M; Jfri, A; Ladha, MA, 2022) |
| "Keloid was identified in 13 boys and 10 girls, accounting for 0." | 1.34 | Prevalence of childhood acne, ephelides, warts, atopic dermatitis, psoriasis, alopecia areata and keloid in Kaohsiung County, Taiwan: a community-based clinical survey. ( Chen, W; Cheng, YW; Lai, CS; Yang, YC, 2007) |
| "Severe cases of nuchal AM may precede acne keloidalis nuchae (AKN)." | 1.30 | Prevalence of acne keloidalis nuchae in football players. ( Gonin, R; Hanke, CW; Knable, AL, 1997) |
| "In the childhood population, atopic eczema and tinea capitis were the most frequent dermatoses, comprising 63% of diagnoses recorded." | 1.30 | A study of the spectrum of skin disease occurring in a black population in south-east London. ( Child, FJ; Du Vivier, AW; Fuller, LC; Higgins, EM, 1999) |
| "Significant scarring is a potential sequela of the second degree burns produced by argon or carbon dioxide laser surgery, and is particularly a risk for children." | 1.27 | Laser surgery for children. ( Brauner, GJ; Schliftman, A, 1987) |
| "Indications for radiotherapy of benign dermatoses have decreased markedly during the past decades." | 1.26 | [Roentgen therapy of dermatoses: indications and hazards]. ( Goldschmidt, H, 1978) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 20 (42.55) | 18.7374 |
| 1990's | 8 (17.02) | 18.2507 |
| 2000's | 4 (8.51) | 29.6817 |
| 2010's | 5 (10.64) | 24.3611 |
| 2020's | 10 (21.28) | 2.80 |
| Authors | Studies |
|---|---|
| Goodman, GJ | 1 |
| Liu, Y | 1 |
| Li, Z | 1 |
| Hu, J | 1 |
| Zhan, S | 1 |
| Wang, M | 1 |
| Wang, L | 1 |
| Chiriac, A | 1 |
| Wollina, U | 1 |
| Jfri, A | 2 |
| Alajmi, A | 2 |
| Alazemi, M | 2 |
| Ladha, MA | 2 |
| Ludwig, RJ | 1 |
| von Stebut, E | 1 |
| Bekkers, VZ | 1 |
| Bik, L | 1 |
| van Huijstee, JC | 1 |
| Wolkerstorfer, A | 1 |
| Prens, EP | 1 |
| van Doorn, MBA | 1 |
| Park, SJ | 1 |
| Shin, SH | 1 |
| Koh, YG | 1 |
| Kim, GH | 1 |
| Rho, NK | 1 |
| Park, KY | 1 |
| Liu, J | 1 |
| Zhang, Z | 1 |
| Wang, X | 1 |
| Li, J | 1 |
| Zhang, W | 1 |
| Wang, Y | 1 |
| Zhao, LT | 1 |
| Gao, LM | 1 |
| Chen, XD | 1 |
| Wu, XY | 1 |
| Scheiba, N | 1 |
| Hartschuh, W | 1 |
| Yeung, H | 1 |
| Kahn, B | 1 |
| Ly, BC | 1 |
| Tangpricha, V | 1 |
| Mitbauerová, A | 1 |
| Čapek, L | 1 |
| Ogawa, R | 1 |
| Zaleski-Larsen, LA | 1 |
| Fabi, SG | 1 |
| McGraw, T | 1 |
| Taylor, M | 1 |
| Guadanhim, LR | 1 |
| Gonçalves, RG | 1 |
| Bagatin, E | 1 |
| Thiboutot, D | 1 |
| Gollnick, H | 1 |
| Bettoli, V | 1 |
| Dréno, B | 1 |
| Kang, S | 1 |
| Leyden, JJ | 1 |
| Shalita, AR | 1 |
| Lozada, VT | 1 |
| Berson, D | 1 |
| Finlay, A | 1 |
| Goh, CL | 1 |
| Herane, MI | 1 |
| Kaminsky, A | 1 |
| Kubba, R | 1 |
| Layton, A | 1 |
| Miyachi, Y | 1 |
| Perez, M | 1 |
| Martin, JP | 1 |
| Ramos-E-Silva, M | 1 |
| See, JA | 1 |
| Shear, N | 1 |
| Wolf, J | 1 |
| Jansen, T | 1 |
| Podda, M | 1 |
| Taylor, SC | 1 |
| Kelly, AP | 1 |
| Dupree, NE | 1 |
| Kimball, AB | 1 |
| Lawrence, RC | 1 |
| DE STEFANO, C | 1 |
| WHEATE, HW | 1 |
| WOODMAN, EN | 1 |
| VIGLIOGLIA, PA | 1 |
| KUHN, BH | 1 |
| WALLACE, HJ | 1 |
| Dogan, G | 1 |
| Yang, YC | 1 |
| Cheng, YW | 1 |
| Lai, CS | 1 |
| Chen, W | 1 |
| Mukherjee, A | 2 |
| Saha, KC | 1 |
| Stegman, SJ | 2 |
| Tromovitch, TA | 1 |
| Thomas, JR | 1 |
| Doyle, JA | 1 |
| Sizov, VM | 1 |
| Jutley, JK | 1 |
| Ng, KY | 1 |
| Cunliffe, WJ | 1 |
| Layton, AM | 1 |
| Wood, EJ | 1 |
| Knable, AL | 1 |
| Hanke, CW | 2 |
| Gonin, R | 1 |
| Fitzpatrick, RE | 1 |
| Ginarte, M | 1 |
| Peteiro, C | 1 |
| Toribio, J | 1 |
| Child, FJ | 1 |
| Fuller, LC | 1 |
| Higgins, EM | 1 |
| Du Vivier, AW | 1 |
| Rintala, AE | 1 |
| Verbov, J | 1 |
| Goldschmidt, H | 2 |
| Lukacs, S | 1 |
| Braun-Falco, O | 1 |
| Harris, H | 1 |
| Halber, S | 1 |
| Salfeld, K | 1 |
| Brauner, GJ | 1 |
| Schliftman, A | 1 |
| Zachariae, H | 1 |
| Sherman, R | 1 |
| Rosenfeld, H | 1 |
| Rubenstein, R | 1 |
| Roenigk, HH | 1 |
| Walther, H | 1 |
| Curth, W | 1 |
| McSorley, J | 1 |
| Dickinson, JT | 1 |
| Rooker, DW | 1 |
| Leonard, JR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Combined Treatment With Nonablative Fractional Laser and Radiofrequency Microneedling for the Treatment of Acne Scars: A Prospective, Randomized, Split-Face Study[NCT05105334] | 20 participants (Anticipated) | Interventional | 2021-11-08 | Not yet recruiting | |||
| Open, Non-comparative, Multicentre Clinical Investigation to Evaluate the Performance and Safety of the Medical Device Plenhyage® (Polymerised Polynucleotides Dermal Filler) in the Treatment of Dermal Tissue Defects[NCT05239117] | 48 participants (Actual) | Interventional | 2022-03-30 | Active, not recruiting | |||
| Comparison of Safety and Efficacy of Tazarotene 0.1% Plus Clindamycin 1% Gel vs. Adapalene 0.1% Plus Clindamycin 1% Gel in the Treatment of Facial Acne Vulgaris: A Randomized Controlled Trial[NCT02721173] | Phase 4 | 60 participants (Actual) | Interventional | 2016-04-30 | Completed | ||
| Autologous Fat Cells Transfer for the Treatment of Atrophic Post Acne Scars: Clinical Trail[NCT05028283] | 69 participants (Actual) | Interventional | 2021-08-19 | Completed | |||
| A Phase 1B Dose Escalating Study of the Safety, Short-Term Engraftment and Action of a Singly-Applied NB01 in Adults With Moderate Acne[NCT03450369] | Phase 1 | 10 participants (Actual) | Interventional | 2018-01-24 | Completed | ||
| Serum apelin12 in Acne Vulgaris[NCT03480503] | 90 participants (Anticipated) | Observational | 2018-05-31 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Engraftment is defined as the percentage of bacteria recovered from hair follicles that are health-associated (NB01) as measured with proprietary quantitative polymerase chain assays. Successful follicular engraftment, defined as both deoR/PanBac >40% and Cas5/PanBac >40% in the Day 2 (24H) ) Biore Strip samples. Cas5/PanBac and deoR/PanBac are the percentages of bacteria in a sample containing the CRISPR associated protein Cas5 and a repressor of porphyrin production deoR, respectively. Pan-Bacterial (PanBac) is a loci found in nearly all bacteria found on the face and thus serves as the denominator to calculate the percentage of bacteria with any loci. (NCT03450369)
Timeframe: 2 Months
| Intervention | Participants (Count of Participants) |
|---|---|
| Low Dose | 2 |
| High Dose | 1 |
To determine longevity of the live biotherapeutic after a single application, swab samples were collected at Baseline, 6, 24 and 48 hours after application, and genotyped as above. For each participant the absolute change, from Baseline, in the percentage of the two loci present in the live biotherapeutic (deoR and Cas5) were calculated. A significant positive change is indicative of the continued presence of the live biotherapeutic. (NCT03450369)
Timeframe: From Baseline to 48 hours after application
| Intervention | % of total bacteria w/ genotype (Mean) | |||||
|---|---|---|---|---|---|---|
| Genotype 1 (deoR), 6 hours | Genotype 1 (deoR), 24 hours | Genotype 1 (deoR), 48 hours | Genotype 2 (Cas 5), 6 hours | Genotype 2 (Cas 5), 24 hours | Genotype 2 (Cas 5), 48 hours | |
| High Dose | 51.2 | 5.2 | 2.8 | 48.4 | 4.4 | 1.8 |
| Low Dose | -0.4 | -4.2 | 13.8 | 12.8 | 3.4 | 3.2 |
Safety profile and tolerability of a singly applied NB01 using the Investigator Assessment of Tolerability Scoring (0 = None; 1 = Slight; 2 = Moderate; 3 = Intense) for Conjunctival Injection. Reference: ClinicalTrials.gov: Investigator Assessment Tolerability Scoring: A Study to Evaluate Tolerability of Two Topical Drug Products in the Treatment of Acne. (NCT03450369)
Timeframe: From Screening to 28 days after application, typically 2 months
| Intervention | Participants (Count of Participants) | ||||||
|---|---|---|---|---|---|---|---|
| Screening, scale = 0 (none) | Day 1 (0 hours), scale = 0 (none) | Day 1 (6 hours), scale = 0 (none) | Day 2, scale = 0 (none) | Day 3, scale = 0 (none) | Day 7, scale = 0 (none) | Day 28, scale = 0 (none) | |
| High Dose | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Low Dose | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
Safety profile and tolerability of a singly applied NB01 using the Investigator Assessment of Tolerability Scoring (0 = None; 1 = Slight; 2 = Moderate; 3 = Intense) for Hyperpigmentation. Reference: ClinicalTrials.gov: Investigator Assessment Tolerability Scoring: A Study to Evaluate Tolerability of Two Topical Drug Products in the Treatment of Acne. (NCT03450369)
Timeframe: From Screening to 28 days after application, typically 2 months
| Intervention | Participants (Count of Participants) | ||||||
|---|---|---|---|---|---|---|---|
| Screening, scale = 0 (none) | Day 1 (0 hours), scale = 0 (none) | Day 1 (6 hours), scale = 0 (none) | Day 2, scale = 0 (none) | Day 3, scale = 0 (none) | Day 7, scale = 0 (none) | Day 28, scale = 0 (none) | |
| High Dose | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Low Dose | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
Safety profile and tolerability of a singly applied NB01 using the Investigator Assessment of Tolerability Scoring (0 = None; 1 = Slight; 2 = Moderate; 3 = Intense) for Irritant/Allergic Contact Dermatitis. Reference: ClinicalTrials.gov: Investigator Assessment Tolerability Scoring: A Study to Evaluate Tolerability of Two Topical Drug Products in the Treatment of Acne. (NCT03450369)
Timeframe: From Screening to 28 days after application, typically 2 months
| Intervention | Participants (Count of Participants) | ||||||
|---|---|---|---|---|---|---|---|
| Screening, scale = 0 (none) | Day 1 (0 hours), scale = 0 (none) | Day 1 (6 hours), scale = 0 (none) | Day 2, scale = 0 (none) | Day 3, scale = 0 (none) | Day 7, scale = 0 (none) | Day 28, scale = 0 (none) | |
| High Dose | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Low Dose | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
Safety profile and tolerability of a singly applied NB01 using the Investigator Assessment of Tolerability Scoring (0 = None; 1 = Slight; 2 = Moderate; 3 = Intense) for Mucosal Toxicity. Reference: ClinicalTrials.gov: Investigator Assessment Tolerability Scoring: A Study to Evaluate Tolerability of Two Topical Drug Products in the Treatment of Acne. (NCT03450369)
Timeframe: From Screening to 28 days after application, typically 2 months
| Intervention | Participants (Count of Participants) | ||||||
|---|---|---|---|---|---|---|---|
| Screening, scale = 0 (none) | Day 1 (0 hours), scale = 0 (none) | Day 1 (6 hours), scale = 0 (none) | Day 2, scale = 0 (none) | Day 3, scale = 0 (none) | Day 7, scale = 0 (none) | Day 28, scale = 0 (none) | |
| High Dose | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Low Dose | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
Safety profile and tolerability of a singly applied NB01 using the Investigator Assessment of Tolerability Scoring (0 = None; 1 = Slight; 2 = Moderate; 3 = Intense) for Ocular Irritation. Reference: ClinicalTrials.gov: Investigator Assessment Tolerability Scoring: A Study to Evaluate Tolerability of Two Topical Drug Products in the Treatment of Acne. (NCT03450369)
Timeframe: From Screening to 28 days after application, typically 2 months
| Intervention | Participants (Count of Participants) | ||||||
|---|---|---|---|---|---|---|---|
| Screening, scale = 0 (none) | Day 1 (0 hours), scale = 0 (none) | Day 1 (6 hours), scale = 0 (none) | Day 2, scale = 0 (none) | Day 3, scale = 0 (none) | Day 7, scale = 0 (none) | Day 28, scale = 0 (none) | |
| High Dose | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Low Dose | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
Safety profile and tolerability of a singly applied NB01 using the Investigator Assessment of Tolerability Scoring (0 = None; 1 = Slight; 2 = Moderate; 3 = Intense) for Skin Dryness. Reference: ClinicalTrials.gov: Investigator Assessment Tolerability Scoring: A Study to Evaluate Tolerability of Two Topical Drug Products in the Treatment of Acne. (NCT03450369)
Timeframe: From Screening to 28 days after application, typically 2 months
| Intervention | Participants (Count of Participants) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Screening, scale = 0 (none) | Screening, scale = 1 (slight) | Day 1 (0 hours), scale = 0 (none) | Day 1 (0 hours), scale = 1 (slight) | Day 1 (6 hours), scale = 0 (none) | Day 1 (6 hours), scale = 1 (slight) | Day 2, scale = 0 (none) | Day 2, scale = 1 (slight) | Day 3, scale = 0 (none) | Day 3, scale = 1 (slight) | Day 7, scale = 0 (none) | Day 28, scale = 0 (none) | Day 28, scale = 1 (slight) | |
| High Dose | 5 | 0 | 5 | 0 | 5 | 0 | 5 | 0 | 5 | 0 | 5 | 5 | 0 |
| Low Dose | 4 | 1 | 4 | 1 | 4 | 1 | 4 | 1 | 4 | 1 | 5 | 3 | 2 |
Safety profile and tolerability of a singly applied NB01 using the Investigator Assessment of Tolerability Scoring (0 = None; 1 = Slight; 2 = Moderate; 3 = Intense) for Skin Erythema. Reference: ClinicalTrials.gov: Investigator Assessment Tolerability Scoring: A Study to Evaluate Tolerability of Two Topical Drug Products in the Treatment of Acne. (NCT03450369)
Timeframe: From Screening to 28 days after application, typically 2 months
| Intervention | Participants (Count of Participants) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Screening, scale = 0 (none) | Screening, scale = 1 (slight) | Day 1 (0 hours), scale = 0 (none) | Day 1 (0 hours), scale = 1 (slight) | Day 1 (0 hours), scale = 2 (moderate) | Day 1 (6 hours), scale = 0 (none) | Day 1 (6 hours), scale = 1 (slight) | Day 1 (6 hours), scale = 2 (moderate) | Day 2, scale = 0 (none) | Day 2, scale = 1 (slight) | Day 3, scale = 0 (none) | Day 3, scale = 1 (slight) | Day 7, scale = 0 (none) | Day 7, scale = 1 (slight) | Day 28, scale = 0 (none) | |
| High Dose | 5 | 0 | 5 | 0 | 0 | 5 | 0 | 0 | 5 | 0 | 5 | 0 | 5 | 0 | 5 |
| Low Dose | 2 | 3 | 3 | 1 | 1 | 3 | 1 | 1 | 4 | 1 | 4 | 1 | 4 | 1 | 5 |
Safety profile and tolerability of a singly applied NB01 using the Investigator Assessment of Tolerability Scoring (0 = None; 1 = Slight; 2 = Moderate; 3 = Intense) for Skin Peeling. Reference: ClinicalTrials.gov: Investigator Assessment Tolerability Scoring: A Study to Evaluate Tolerability of Two Topical Drug Products in the Treatment of Acne. (NCT03450369)
Timeframe: From Screening to 28 days after application, typically 2 months
| Intervention | Participants (Count of Participants) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Screening, scale = 0 (none) | Screening, scale = 1 (slight) | Day 1 (0 hours), scale = 0 (none) | Day 1 (0 hours), scale = 1 (slight) | Day 1 (6 hours), scale = 0 (none) | Day 1 (6 hours), scale = 1 (slight) | Day 2, scale = 0 (none) | Day 3, scale = 0 (none) | Day 7, scale = 0 (none) | Day 28, scale = 0 (none) | |
| High Dose | 5 | 0 | 5 | 0 | 5 | 0 | 5 | 5 | 5 | 5 |
| Low Dose | 3 | 2 | 4 | 1 | 4 | 1 | 5 | 5 | 5 | 5 |
"Number of participants with a changed Investigator Global Assessment (IGA) score after single application of NB01; positive number if grade is reduced (e.g. from 3 to 2) or negative number is IGA grade increased.~The Investigator Global Assessment 5-Point Score is a standard FDA acne assessment tool with scoring as follows:~Grade 0-Clear (Clear skin with no inflammatory or non-inflammatory lesions. The category of clear should represent true absence of disease) Grade1-Almost Clear (A few scattered comedones and no more than one small papule) Grade 2-Mild (Some comedones, some papules and pustules; no nodules) Grade 3-Moderate (Many comedones, papules and pustules; one nodule may be present) Grade 4-Severe (Covered with comedones, numerous papules and pustules and no more than a few nodular lesions)" (NCT03450369)
Timeframe: 28 Days
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| Participants with changed IGA @ 6 hours | Participants with changed IGA @ 1 day | Participants with changed IGA @ 2 days | Participants with changed IGA @ 6 days | Participants with changed IGA @ 28 days | |
| High Dose | 0 | 0 | 0 | 0 | 0 |
| Low Dose | 0 | 0 | 0 | 0 | 2 |
Absolute Lesion Count: All Lesions for the Whole Face; with higher numbers of lesion representing worsening or more severe acne (NCT03450369)
Timeframe: From Screening to 28 days after application, typically 2 months
| Intervention | count of lesions (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Screening | Day 1 (0 hours) | Day 1 (6 hours) | Day 2 | Day 3 | Day 7 | Day 28 | |
| High Dose | 38.8 | 42.6 | 39.8 | 38.2 | 35.4 | 34.2 | 32.6 |
| Low Dose | 49.4 | 22.6 | 21.0 | 31.6 | 32.2 | 25.6 | 25.8 |
10 reviews available for khellin and Acne
| Article | Year |
|---|---|
[Inflammatory dermatoses in skin of color].
Topics: Acne Vulgaris; Dermatitis, Atopic; Humans; Hyperpigmentation; Keloid; Psoriasis; Rosacea; Skin Pigme | 2023 |
Efficacy and safety of needle-free jet injector-assisted intralesional treatments in dermatology-a systematic review.
Topics: Acne Vulgaris; Dermatology; Fluorouracil; Humans; Keloid; Treatment Outcome; Triamcinolone Acetonide | 2023 |
Dermatologic Conditions in Transgender Populations.
Topics: Acne Vulgaris; Alopecia; Hirsutism; Hormone Replacement Therapy; Humans; Keloid; Sex Reassignment Pr | 2019 |
Acne Scar Treatment: A Multimodality Approach Tailored to Scar Type.
Topics: Acne Vulgaris; Chemexfoliation; Cicatrix; Cicatrix, Hypertrophic; Combined Modality Therapy; High-In | 2016 |
Acne Scar Treatment: A Multimodality Approach Tailored to Scar Type.
Topics: Acne Vulgaris; Chemexfoliation; Cicatrix; Cicatrix, Hypertrophic; Combined Modality Therapy; High-In | 2016 |
Acne Scar Treatment: A Multimodality Approach Tailored to Scar Type.
Topics: Acne Vulgaris; Chemexfoliation; Cicatrix; Cicatrix, Hypertrophic; Combined Modality Therapy; High-In | 2016 |
Acne Scar Treatment: A Multimodality Approach Tailored to Scar Type.
Topics: Acne Vulgaris; Chemexfoliation; Cicatrix; Cicatrix, Hypertrophic; Combined Modality Therapy; High-In | 2016 |
New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group.
Topics: Acne Vulgaris; Administration, Oral; Administration, Topical; Algorithms; Anti-Bacterial Agents; Chr | 2009 |
New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group.
Topics: Acne Vulgaris; Administration, Oral; Administration, Topical; Algorithms; Anti-Bacterial Agents; Chr | 2009 |
New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group.
Topics: Acne Vulgaris; Administration, Oral; Administration, Topical; Algorithms; Anti-Bacterial Agents; Chr | 2009 |
New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group.
Topics: Acne Vulgaris; Administration, Oral; Administration, Topical; Algorithms; Anti-Bacterial Agents; Chr | 2009 |
New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group.
Topics: Acne Vulgaris; Administration, Oral; Administration, Topical; Algorithms; Anti-Bacterial Agents; Chr | 2009 |
New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group.
Topics: Acne Vulgaris; Administration, Oral; Administration, Topical; Algorithms; Anti-Bacterial Agents; Chr | 2009 |
New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group.
Topics: Acne Vulgaris; Administration, Oral; Administration, Topical; Algorithms; Anti-Bacterial Agents; Chr | 2009 |
New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group.
Topics: Acne Vulgaris; Administration, Oral; Administration, Topical; Algorithms; Anti-Bacterial Agents; Chr | 2009 |
New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group.
Topics: Acne Vulgaris; Administration, Oral; Administration, Topical; Algorithms; Anti-Bacterial Agents; Chr | 2009 |
New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group.
Topics: Acne Vulgaris; Administration, Oral; Administration, Topical; Algorithms; Anti-Bacterial Agents; Chr | 2009 |
New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group.
Topics: Acne Vulgaris; Administration, Oral; Administration, Topical; Algorithms; Anti-Bacterial Agents; Chr | 2009 |
New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group.
Topics: Acne Vulgaris; Administration, Oral; Administration, Topical; Algorithms; Anti-Bacterial Agents; Chr | 2009 |
New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group.
Topics: Acne Vulgaris; Administration, Oral; Administration, Topical; Algorithms; Anti-Bacterial Agents; Chr | 2009 |
New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group.
Topics: Acne Vulgaris; Administration, Oral; Administration, Topical; Algorithms; Anti-Bacterial Agents; Chr | 2009 |
New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group.
Topics: Acne Vulgaris; Administration, Oral; Administration, Topical; Algorithms; Anti-Bacterial Agents; Chr | 2009 |
New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group.
Topics: Acne Vulgaris; Administration, Oral; Administration, Topical; Algorithms; Anti-Bacterial Agents; Chr | 2009 |
[Therapy of acne scars].
Topics: Acne Vulgaris; Atrophy; Chemexfoliation; Cicatrix; Cicatrix, Hypertrophic; Dermabrasion; Evidence-Ba | 2010 |
Cosmetic dermatologic surgery.
Topics: Acne Vulgaris; Alopecia; Chemexfoliation; Cicatrix; Collagen; Dermabrasion; Facial Dermatoses; Femal | 1982 |
The therapeutic uses of topical vitamin A acid.
Topics: Acne Vulgaris; Animals; Callosities; Cocarcinogenesis; Fox-Fordyce Disease; Humans; Ichthyosis; Kelo | 1981 |
[Keloid or Hypertrophic scar?].
Topics: Acne Vulgaris; Cicatrix, Hypertrophic; Diagnosis, Differential; Humans; Keloid; Risk Assessment; Wou | 1996 |
[Therapy of skin and venereal diseases. Review of the literature of 1967-68].
Topics: Acne Vulgaris; Alopecia; Balanitis; Candidiasis; Dermatitis, Occupational; Dermatomycoses; Diaper Ra | 1969 |
2 trials available for khellin and Acne
| Article | Year |
|---|---|
Cold anesthesia for pain reduction during intralesional steroid injection for nodulocystic acne.
Topics: Acne Vulgaris; Anesthesia; Humans; Injections, Intralesional; Keloid; Pain; Steroids; Treatment Outc | 2023 |
Treatment of inflamed hypertrophic scars using intralesional 5-FU.
Topics: Acne Vulgaris; Adult; Aged; Anti-Inflammatory Agents; Antimetabolites; Cicatrix; Female; Fluorouraci | 1999 |
35 other studies available for khellin and Acne
| Article | Year |
|---|---|
Commentary on A Neglected Acne Scar Type: Papular Acne Scars and Their Correlations With Keloid Scars.
Topics: Acne Vulgaris; Cicatrix; Cicatrix, Hypertrophic; Humans; Keloid | 2021 |
Treatment of acne by subcutaneous injection of low-concentration 5-Fluorouracil.
Topics: Acne Vulgaris; Fluorouracil; Humans; Injections, Intralesional; Injections, Subcutaneous; Keloid | 2022 |
Spontaneous keloids during isotretinoin treatment for acne.
Topics: Acne Vulgaris; Administration, Oral; Dermatologic Agents; Humans; Isotretinoin; Keloid; Treatment Ou | 2022 |
Acne Scars: An Update on Management
Topics: Acne Vulgaris; Atrophy; Humans; Keloid; Quality of Life; Treatment Outcome; Wound Healing | 2022 |
Acne Scars: An Update on Management
Topics: Acne Vulgaris; Atrophy; Humans; Keloid; Quality of Life; Treatment Outcome; Wound Healing | 2022 |
Acne Scars: An Update on Management
Topics: Acne Vulgaris; Atrophy; Humans; Keloid; Quality of Life; Treatment Outcome; Wound Healing | 2022 |
Acne Scars: An Update on Management
Topics: Acne Vulgaris; Atrophy; Humans; Keloid; Quality of Life; Treatment Outcome; Wound Healing | 2022 |
Rare Complication of Massive Depigmentation After Postoperative Treatment of Giant Keloid Combined With Strontium-90.
Topics: Acne Vulgaris; Adolescent; Humans; Keloid; Postoperative Period; Recurrence; Strontium Radioisotopes | 2023 |
A massive mandibular keloid with severe infection: What is your treatment?
Topics: Acne Vulgaris; Aminolevulinic Acid; Humans; Keloid; Photochemotherapy; Photosensitizing Agents; Trea | 2021 |
[Atypical keloids with an unusual myofibroblastic differentiation in a patient with acne vulgaris].
Topics: Acne Vulgaris; Adrenal Cortex Hormones; Cicatrix, Hypertrophic; Cryotherapy; Humans; Injections, Int | 2022 |
A method of scar evaluation using non-contact 3D scanner.
Topics: Acne Vulgaris; Adult; Aged; Female; Humans; Imaging, Three-Dimensional; Keloid; Male; Middle Aged | 2013 |
Observational retrospective study evaluating the effects of oral isotretinoin in keloids and hypertrophic scars.
Topics: Acne Vulgaris; Administration, Oral; Adolescent; Adult; Case-Control Studies; Cicatrix, Hypertrophic | 2016 |
Health disparities in arthritis and musculoskeletal and skin diseases-the dermatology session: National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, Maryland, December 15-16, 2000.
Topics: Acne Vulgaris; Black People; Health Surveys; Humans; Keloid; Minority Groups; Racial Groups; Researc | 2002 |
Carcinoma with adenomatous structure in skin transplanted in the region of keloid acne of the neck.
Topics: Acne Vulgaris; Carcinoma; Head and Neck Neoplasms; Humans; Keloid; Neoplasms; Skin; Skin Transplanta | 1960 |
An unusual case of acne keloid.
Topics: Acne Keloid; Acne Vulgaris; Humans; Keloid; Leprosy | 1962 |
THE TREATMENT OF SKIN CONDITIONS IN THE RADIOTHERAPY DEPARTMENT.
Topics: Acne Vulgaris; Geriatrics; Hair Removal; Humans; Keloid; Keratosis; Neoplasms; Pruritus; Radiotherap | 1963 |
[INTRALESIONAL EFFECTS OF BETAMETHASONE WITH SPECIAL REFERENCE TO ITS HISTOPATHOLOGIC STUDY].
Topics: Acne Vulgaris; Betamethasone; Humans; Injections; Keloid; Leprosy; Lichen Planus; Lupus Erythematosu | 1963 |
CLINICAL EVALUATION OF A STEROID-VITAMIN A-ESTROGEN LOTION.
Topics: Acne Vulgaris; Alopecia Areata; Dermatitis; Dermatitis, Atopic; Dermatology; Estrogens; Humans; Hydr | 1963 |
Keloid associated with acne in a young girl.
Topics: Acne Vulgaris; Female; Humans; Keloid | 1950 |
Possible isotretinoin-induced keloids in a patient with Behçet's disease.
Topics: Acne Vulgaris; Adult; Behcet Syndrome; Drug Eruptions; Humans; Isotretinoin; Keloid; Keratolytic Age | 2006 |
Prevalence of childhood acne, ephelides, warts, atopic dermatitis, psoriasis, alopecia areata and keloid in Kaohsiung County, Taiwan: a community-based clinical survey.
Topics: Acne Vulgaris; Alopecia Areata; Chi-Square Distribution; Child; Cross-Sectional Studies; Dermatitis, | 2007 |
Delayed type hypersensitivity reaction to cutaneous antigen in keloid.
Topics: Acne Vulgaris; Adolescent; Adult; Female; Humans; Hypersensitivity, Delayed; Isoantigens; Keloid; Ma | 1982 |
[The diagnosis and treatment of hypertrophic and keloid scars].
Topics: Acne Vulgaris; Burns; Cicatrix, Hypertrophic; Cryosurgery; Humans; Keloid; Skin | 1994 |
Analysis of collagen composition in acne keloids.
Topics: Acne Vulgaris; Biopsy; Cell Division; Cells, Cultured; Collagen; Fibroblasts; Humans; Keloid; Procol | 1993 |
Prevalence of acne keloidalis nuchae in football players.
Topics: Acne Keloid; Acne Vulgaris; Adolescent; Adult; Age Factors; Analysis of Variance; Black People; Conf | 1997 |
Keloid formation induced by isotretinoin therapy.
Topics: Acne Vulgaris; Adolescent; Humans; Isotretinoin; Keloid; Keratolytic Agents; Male | 1999 |
A study of the spectrum of skin disease occurring in a black population in south-east London.
Topics: Acne Vulgaris; Acrodermatitis; Adult; Black or African American; Black People; Child; Cohort Studies | 1999 |
The place of intralesional steroid therapy in dermatology.
Topics: Acne Vulgaris; Adult; Aged; Alopecia Areata; Humans; Injections, Jet; Keloid; Lupus Erythematosus, S | 1976 |
[Roentgen therapy of dermatoses: indications and hazards].
Topics: Acne Vulgaris; Eczema; Foot Dermatoses; Humans; Keloid; Lichen Planus; Lymphocytosis; Neoplasms, Rad | 1978 |
Radiotherapy of benign dermatoses: indications, practice, and results.
Topics: Acne Vulgaris; Bacterial Infections; Dupuytren Contracture; Eczema; Female; Hemangioma; Herpes Simpl | 1978 |
Acne keloidalis aggravated by football helmets.
Topics: Acne Vulgaris; Adult; Football; Head Protective Devices; Humans; Keloid; Male; Scalp Dermatoses | 1992 |
[Dermabrasion--indications, technic, possibilities, complications].
Topics: Acne Vulgaris; Dermabrasion; Female; Humans; Keloid; Male; Rhinophyma; Tattooing | 1985 |
Laser surgery for children.
Topics: Acne Vulgaris; Child; Cicatrix; Hemangioma; Humans; Keloid; Laser Therapy; Pigmentation Disorders; S | 1987 |
Delayed wound healing and keloid formation following argon laser treatment or dermabrasion during isotretinoin treatment.
Topics: Acne Vulgaris; Adult; Aged; Dermabrasion; Female; Humans; Isomerism; Isotretinoin; Keloid; Laser The | 1988 |
Experience with the Nd:YAG laser in the treatment of keloid scars.
Topics: Acne Vulgaris; Adolescent; Child; Cicatrix; Humans; Keloid; Laser Therapy; Male; Skin; Wound Healing | 1988 |
Atypical keloids after dermabrasion of patients taking isotretinoin.
Topics: Acne Vulgaris; Adult; Dermabrasion; Female; Humans; Isotretinoin; Keloid; Male; Microbial Collagenas | 1986 |
Multiple keloids.
Topics: Acne Vulgaris; Adult; Aged; Black or African American; Female; Humans; Keloid; Male; Middle Aged; Sk | 1971 |
Minor surgery for benign and malignant facial lesions.
Topics: Acne Vulgaris; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Cicatrix; Cortisone; Curettage; Cyst | 1974 |